Why the study?
Does dalteparin prevent veno-pulmonary thromboembolic diseases in pregnant women at risk?
Population
24 women carrying 27 pregnancies with known risk of veno-pulmonary thromboembolic diseases in pregnancy
Design
Cohort
Follow-up
6 weeks postpartum
Authors
Loading...
May support dalteparin prophylaxis in at-risk pregnancies; leaves open need for randomized confirmation of efficacy.
Does dalteparin prevent veno-pulmonary thromboembolic diseases in pregnant women at risk?
Prophylactic dalteparin during pregnancy in women at risk for thromboembolic diseases was effective and safe, with no thromboembolic events or side effects observed.
Rasmussen et al. (1994) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: